Clinical Trial Results: High Dose IL-2 in Combination With Anti-PD-1 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose interleukin-2 in combination with anti-PD-1 in melanoma and renal cell carcinoma (metastatic); study terminated with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma Metastatic

Drugs mentioned

• Anti-PD-1
• Interleukin-2 (high-dose) (Interleukin-2)

Snippet

Sponsor: Gregory Daniels | Conditions: Melanoma, Renal Cell Carcinoma, Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2026-08-06